Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    CLN-081

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Taiho, Cullinan Start NDA Submission For Zipalertinib In NSCLC
    Taiho, Cullinan Start NDA Submission For Zipalertinib In NSCLC

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cel-302621302.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Taiho Oncology, Cullinan Therapeutics Present Zipalertinib Data
    Taiho Oncology, Cullinan Therapeutics Present Zipalertinib Data

    13 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-in-patients-with-nsclc-with-egfr-mutations-and-active-brain-metastases-at-the-esmo-congress-2025-302581514.html

    PR NEWSWIRE
    13 Oct 2025
    Share Share
    Cullinan, Taiho's NSCLC Shows 'Strong Activity', Paves Way to FDA
    Cullinan, Taiho's NSCLC Shows 'Strong Activity', Paves Way to FDA

    10 Sep 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/cullinan-taihos-nsclc-hopeful-shows-strong-activity-clearing-road-to-fda

    BIOSPACE
    10 Sep 2025
    Share Share
    Taiho & Cullinan Present Zipalertinib Data at IASLC Conference
    Taiho & Cullinan Present Zipalertinib Data at IASLC Conference

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer-302549926.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    Taiho Oncology's Zipalertinib Abstract Accepted for ESMO
    Taiho Oncology's Zipalertinib Abstract Accepted for ESMO

    25 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-announces-acceptance-of-abstract-for-zipalertinib-at-the-esmo-congress-2025-302513640.html

    PR NEWSWIRE
    25 Jul 2025
    Share Share
    Taiho Oncology, Cullinan Therapeutics' Zipalertinib abstracts
    Taiho Oncology, Cullinan Therapeutics' Zipalertinib abstracts

    22 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-announce-acceptance-of-abstracts-for-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer-302510269.html

    PR NEWSWIRE
    22 Jul 2025
    Share Share